Structure Therapeutics (GPCR) Competitors $32.71 -0.07 (-0.21%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GPCR vs. JAZZ, LEGN, MDGL, ELAN, BPMC, NUVL, CYTK, CORT, VKTX, and IONSShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Jazz Pharmaceuticals (JAZZ), Legend Biotech (LEGN), Madrigal Pharmaceuticals (MDGL), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Nuvalent (NUVL), Cytokinetics (CYTK), Corcept Therapeutics (CORT), Viking Therapeutics (VKTX), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry. Structure Therapeutics vs. Jazz Pharmaceuticals Legend Biotech Madrigal Pharmaceuticals Elanco Animal Health Blueprint Medicines Nuvalent Cytokinetics Corcept Therapeutics Viking Therapeutics Ionis Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Is GPCR or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 11.60% compared to Structure Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 29.30% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.37% -15.68% Jazz Pharmaceuticals 11.60%29.30%9.72% Does the MarketBeat Community favor GPCR or JAZZ? Jazz Pharmaceuticals received 1092 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Structure Therapeutics an outperform vote while only 80.66% of users gave Jazz Pharmaceuticals an outperform vote. CompanyUnderperformOutperformStructure TherapeuticsOutperform Votes2686.67% Underperform Votes413.33%Jazz PharmaceuticalsOutperform Votes111880.66% Underperform Votes26819.34% Which has more volatility & risk, GPCR or JAZZ? Structure Therapeutics has a beta of -3.23, indicating that its stock price is 423% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Do insiders and institutionals have more ownership in GPCR or JAZZ? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend GPCR or JAZZ? Structure Therapeutics presently has a consensus target price of $86.80, indicating a potential upside of 165.36%. Jazz Pharmaceuticals has a consensus target price of $175.53, indicating a potential upside of 47.21%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Structure Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Jazz Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable earnings & valuation, GPCR or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$89.62M-$0.74-44.20Jazz Pharmaceuticals$3.83B1.88$414.83M$7.1016.79 Does the media prefer GPCR or JAZZ? In the previous week, Jazz Pharmaceuticals had 6 more articles in the media than Structure Therapeutics. MarketBeat recorded 19 mentions for Jazz Pharmaceuticals and 13 mentions for Structure Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.65 beat Structure Therapeutics' score of 0.41 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive SummaryJazz Pharmaceuticals beats Structure Therapeutics on 12 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87B$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-44.2010.61125.0817.74Price / SalesN/A243.751,182.0574.25Price / CashN/A22.1633.7232.53Price / Book3.355.474.684.68Net Income-$89.62M$153.61M$119.45M$226.08M7 Day Performance-10.06%-4.32%-2.46%-2.03%1 Month Performance-17.19%-8.61%-4.08%0.07%1 Year Performance-38.81%28.79%29.81%24.61% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.2818 of 5 stars$32.71-0.2%$86.80+165.4%-38.8%$1.88BN/A-44.20136Analyst RevisionJAZZJazz Pharmaceuticals4.9172 of 5 stars$119.24+2.1%$175.53+47.2%-1.2%$7.06B$3.83B16.792,800Analyst ForecastLEGNLegend Biotech1.7588 of 5 stars$40.14+4.5%$81.46+102.9%-33.7%$7.00B$285.14M0.001,800Analyst RevisionMDGLMadrigal Pharmaceuticals3.7989 of 5 stars$317.09+0.9%$347.33+9.5%+66.8%$6.85BN/A-12.6490Analyst ForecastELANElanco Animal Health4.1102 of 5 stars$13.44+1.0%$17.14+27.6%+13.1%$6.58B$4.42B33.609,300BPMCBlueprint Medicines2.713 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.02B$249.38M-44.93640Analyst ForecastNUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040CYTKCytokinetics3.8052 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$5.88B$3.22M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageCORTCorcept Therapeutics4.6673 of 5 stars$56.09+3.3%$65.25+16.3%+116.2%$5.88B$482.38M44.52300VKTXViking Therapeutics4.7705 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A0.0020Analyst ForecastGap UpIONSIonis Pharmaceuticals4.2197 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$788M0.00800 Related Companies and Tools Related Companies Jazz Pharmaceuticals Alternatives Legend Biotech Alternatives Madrigal Pharmaceuticals Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Cytokinetics Alternatives Corcept Therapeutics Alternatives Viking Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GPCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GPCR Stock Alerts